

## CENTRAL INTELLIGENCE AGENCY

## INFORMATION REPORT

This Document contains information affecting the National Defense of the United States, within the meaning of Title 18, Sections 793 and 794, of the U.S. Code, as amended. Its transmission or revelation of its contents to or receipt by an unauthorized person is prohibited by law. The reproduction of this form is prohibited.

SECRET/CONTROL - U.S. OFFICIALS ONLY

25X1

COUNTRY	East Germany	REPORT	
SUBJECT	Production for 1954 at Jenapharm	DATE DISTR.	22 June 1954
DATE OF INFO.		NO. OF PAGES	2
PLACE ACQUIRED		REQUIREMENT NO.	RD 634606
		REFERENCES	25X1

THE SOURCE EVALUATIONS IN THIS REPORT ARE DEFINITIVE.  
THE APPRAISAL OF CONTENT IS TENTATIVE.  
(FOR KEY SEE REVERSE)

25X1

## 1. Planned 1954 production of VEB Jenapharm follows:

<u>Item</u>	<u>Unit</u>	<u>Planned 1954 Production</u>
Penicillin G (total)	Billion IU	3,000
including:		
Penicillin G	"	1,800
Jenacillin	"	1,200
Chloronitrin	Kg	1,200
Streptomycin	"	900
Jenacain - DAB 6	"	2,500
Thebethion	"	1,750
Isotebezid (sic)	"	250
<u>Nikotinsaeureamizid (sic)</u>	"	1,500
Anesthesin - DAB 6	"	3,600
Eystamin - Chlorhydrate	"	120
Ascorvit - Vitamin C	"	2,400
Decrystol - Vitamin D 2	"	160
Vitamin B 1	"	120
Tachystin (sic)	"	36
Scopolamine	"	25
Morphinhydrochlorium	"	250
Codeinphosphoricum	"	125
L-Nor-Adrenalin	"	150
BCG - Injection	Ltr	250
(Innocation against tuberculosis)		

## 2. Some of the items in paragraph one will probably be produced elsewhere, since Jenapharm lacks any possibilities for future expansion, either in personnel

SECRET/CONTROL - U.S. OFFICIALS ONLY

STATE	X	ARMY	X	NAVY	X	AIR	X	FBI		AEC		OSI Ev	x	ORR Ev	x
-------	---	------	---	------	---	-----	---	-----	--	-----	--	--------	---	--------	---

(Note: Washington Distribution Indicated By "X"; Field Distribution By "#".)

SECRET/CONTROL - U.S. OFFICIALS ONLY

- 2 -

or location. In the future, the plant will probably restrict itself to the production of antibiotics and vitamins.

3. The Microbiological Institute at Zeiss-Schott has now assumed the larger share of the scientific preparatory work.
4. The 1953 production plan for Jenapharm was filled by only 92.3%.
5. The xanthocillin of the Arzneimittelwerke, Dresden-Radebeul was developed at Jenapharm. However, it could not be manufactured at Jenapharm because of the lack of space.

SECRET/CONTROL - U.S. OFFICIALS ONLY